Acute generalized exanthematous pustulosis: A retrospective study of 51 cases in Taiwan  by Lee, Yung-Yi & Chung, Wen-Hung
lable at ScienceDirect
DERMATOLOGICA SINICA 32 (2014) 137e140Contents lists avaiDermatologica Sinica
journal homepage: http: / /www.derm-sinica.comORIGINAL ARTICLEAcute generalized exanthematous pustulosis: A retrospective study
of 51 cases in Taiwan
Yung-Yi Lee 1,2, Wen-Hung Chung 1,2,*
1Department of Dermatology, Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Taipei, Linkou,
and Keelung Branches, Taiwan
2College of Medicine, Chang Gung University, Taoyuan, Taiwana r t i c l e i n f o
Article history:
Received: Dec 5, 2013
Revised: Dec 26, 2013
Accepted: Dec 26, 2013
Keywords:
acute generalized exanthematous pustulosis
retrospective study
TaiwaneseConﬂicts of interest: The authors declare that the
ﬁnancial conﬂicts of interest related to the subject ma
this article.
* Corresponding author. Department of Dermato
Clinical and Research Center, Chang Gung Memorial




1027-8117/$ e see front matter Copyright  2014, Ta
http://dx.doi.org/10.1016/j.dsi.2013.12.004a b s t r a c t
Background/Objective: Acute generalized exanthematous pustulosis (AGEP) is a severe cutaneous adverse
drug reaction characterized by fever and numerous sterile non-follicular pustules. It is mainly attributed
to drugs, although other factors have been implicated. The objective of this study was to evaluate the
clinical and histological features of AGEP in a Taiwanese population.
Methods: In this retrospective study, we reviewed patients diagnosed with AGEP with a EuroSCAR
(RegiSCAR) validation score more than 4 (>4, probable to deﬁnite cases), between 1992 and 2012 at the
Chang Gung Memorial Hospital in Taiwan. Demographic, clinical and laboratory data, pathologic ﬁndings,
and disease causality were analyzed.
Results: A total of 51 patients were included in this study, with 34 (66.7%) patients being diagnosed with
AGEP with drug causality, and 17 (33.3%) patients being diagnosed with AGEP without drug causality.
Cases of AGEP with drug causality showed an older average age, and a signiﬁcantly higher rate of pre-
vious drug hypersensitivity history compared to cases of AGEP without drug causality (p ¼ 0.0018). None
of the patients had a history of psoriasis or had developed psoriasis at the 1-year follow-up. A total of 12
cases (23.5%) had systemic involvement, including liver and kidneys. Penicillin or aminopenicillin (17.6%)
and cephalosporins (17.6%) were the most common causative drug groups related to AGEP. In AGEP
patients without drug causality, three cases of pathogen infections were identiﬁed (1 case of myco-
plasma, Coxsackie virus, and Epstein-Barr virus, respectively).
Conclusion: We found that beta-lactam antibiotics were the major drug class responsible for inducing
AGEP in a Taiwanese population, but that some infectious pathogens may also contribute to AGEP
development.
Copyright  2014, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. All rights reserved.Introduction
In 1968, Baker and Ryan1 ﬁrst reported on ﬁve patients with drug-
related pustular eruptions of an acute course, who had no history of
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iwanese Dermatological Associatiopustulosis (AGEP) was later introduced by Beylot et al2 in 1980.
Subsequently, AGEP was better characterized by Roujeau et al3 and
Chang et al,4 and AGEP is now recognized as a disease entity that is
distinct from pustular psoriasis.
AGEP is associated with three main characteristics: (1) an
acute generalized formation of numerous, non-follicular, intra-
epidermal, or subcorneal sterile pustules (<5 mm) on an exten-
sive erythematous background in the absence of bacterial
infection, especially on the main ﬂexural folds, as well as on
other parts of the body and face; (2) the appearance of neutro-
phils after T cell inﬁltration; and (3) the possibility of inducing
the dermatologic reaction by patch testing with the corre-
sponding drug. Viral infections,5 dietary supplements, and hy-
persensitivity to mercury, radiation, and spider bites6 have all
been reported as possible causes of AGEP; however, approxi-
mately 90% of AGEP cases can be attributed to the use of systemicn. Published by Elsevier Taiwan LLC. All rights reserved.
Figure 1 Multiple diffuse erythematous maculopatches studded with several pinpoint,
non-follicular pustules with accentuation on the ﬂexural areas in a 34-year-old female
patient with drug-induced AGEP.
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lides.6 In this study, we reviewed the clinical and laboratory
characteristics of 51 patients with AGEP admitted to the Chang
Gung Memorial Hospital between 1992 and 2012, to determine
the causes of AGEP in a Taiwanese population.Figure 2 (A) Multiple well-demarcated, erythematous plaques with central purpura on bilat
closer view revealed multiple pustules on the erythematous plaques.Methods
Patients admitted to the four different branches of Chang Gung
Memorial Hospital Health System in Taiwan between 1992 and
2012, and diagnosed with AGEP were analyzed. All cases were
assessed by two dermatologists who either evaluated the pa-
tients directly, or reviewed photographs, histological data, and
clinical information. Information regarding clinical features,
laboratory ﬁndings, treatment regimens, and medical and family
histories was recorded. A diagnosis of AGEP was based on the
criteria from the AGEP scoring system established by the Euro-
SCAR study group.7 Similarly, criteria for the AGEP validation
score were obtained from a multinational European study
(EuroSCAR). The AGEP validation score is a standardized scoring
system and based on clinical features and histopathology. A pa-
tient with an AGEP validation score between 5 and 7 is deﬁned as
a probable case, whereas a score between 8 and 12 is deﬁned as a
deﬁnite case. In this study, we excluded patients with an AGEP
validation score <5.
The Naranjo algorithm8 was used to determine the causality of
the suspected adverse drug reactions (ADRs). Brieﬂy, these
assessment methods included prior drug reaction history, clinical
manifestations of typical drug reactions, chronology or temporal
relationship between drug use and onset of reaction, rechallenge,
dechallenge, or improvement after discontinuation of suspected
drugs, and the notoriety of suspected drugs. The patients were
subsequently divided into two groups based on the presence or
absence of causative drugs, and the two groups were compared in
terms of age, sex, systemic symptoms (such as fever, myalgia, or
headaches), duration of disease, history of drug hypersensitivity,
and laboratory data.
Results
A total of 51 cases fulﬁlled the AGEP diagnostic criteria with a
validation score >4. Of these patients, 34 cases (66.7%) were
identiﬁed to have drug causality, whereas 17 cases (33.3%) were not
associated with a causative drug (Figures 1 and 2). The mean age of
patients with AGEP with drug causality was 53.6 years, which was
signiﬁcantly higher than the age of patients with AGEP without
drug causality (30.6 years). No patients in the AGEP without cau-
sality group had a history of hypersensitivity. In contrast, 41.2% oferal thighs in a 40-year-old woman diagnosed with AGEP without drug causality. (B) A
Table 1 Demographic data, disease symptoms, andmedical history of AGEP patients
with or without drug causality.
AGEP with drug
causality,
n ¼ 34 (66.7%)
AGEP without
drug causality,
n ¼ 17 (33.3%)
Sex, n (%)
Male 10 (29.4) 5 (29.4)
Female 24 (70.6) 12 (70.6)




Mucosal involvement, n (%) 3 (8.8) 4 (23.5)
Disease duration of AGEP,
d, mean  SD
10  3.4 10.2  2.6
Occurrence of fever, n (%) 28 (82.4) 11 (64.7)
AGEP score, mean  SD 7.9  1.6 7.7  1.7
Underlying diseases,a n (%) 22 (64.7) 6 (35.3)
Psoriasis history, n 0 0
a Underlying diseases included type II diabetes mellitus, hypertension, hyper-
lipidemia, chronic kidney disease, cancer, and stroke.







PMN exocytosis, n (%) 25 (89.3) 16 (94.1)
Subcorneal or intraepidermal
pustules, n (%)
28 (100) 17 (100)
Spongiosis, n (%) 14 (50) 9 (52.9)
Dyskeratosis and necrosis of
keratinocytes, n (%)
4 (14.3) 5 (29.4)
Munro’s microabscess, n (%) 0 (0) 0 (0)
Psoriasiform hyperplasia, n (%) 0 (0) 0 (0)
RBC exocytosis, n (%) 1 (3.6) 0 (0)
Papillary edema, n (%) 7 (25) 3 (17.6)
Perivascular inﬁltration, n (%) 28 (100) 17 (100)
Leukocytoclastic vasculitis, n (%) 0 (0) 1 (5.9)
Capillary dilatation, n (%) 3 (10.7) 1 (5.9)
Dermal inﬁltrates of eosinophils, n (%) 9 (32.1) 7 (43.6)
PMN ¼ polymorphonuclear neutrophil; RBC ¼ red blood cell.
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persensitivity (0% vs. 41.2%, p ¼ 0.0018). A higher rate of comor-
bidity was found in AGEP with drug causality patients (64.7%),
compared to the AGEP without drug causality group (35.3%). Fever,
one of the typical symptoms associated with AGEP, was present in
82.4% of AGEP with drug causality patients, and in 64.7% of AGEP
without drug causality patients. No patients had either medical or
family histories of psoriasis. In addition, none of the patients in this
study developed psoriasis during the 1-year follow-up period. The
AGEP duration and AGEP score did not differ signiﬁcantly between
the two groups (Table 1).
Beta-lactam antibiotics [penicillin or aminopenicillin (17.6%),
and cephalosporins (17.6%)] were the major drugs related to AGEP
in this population. Additionally, there were three cases (8.8%)
associated with the use of Chinese herbs, and 11 patients had takenTable 2 Clinical presentations of AGEP patients with or without drug causality.
Clinical variants







Hepatitis 1.5 times o
>3 times o
Acute renal insufﬁciency 1.5 times o








a Neutrophilia, value> 7000/mL (normal value< 7500/mL); eosinophilia, value> 700/mL
protein, normal value range 0e5 mg/L
b ALT, alanine aminotransferase, normal value 40 U/L; mild hepatitis was determine
c Cr, creatinine, normal value range 0.4e1.3 mg/dL; acute renal failure was determine
d Penicillin or aminopenicillin included two dicloxacillin and four amoxicillin cases;
quinolones included two ciproﬂoxacin, one oﬂoxacin, and one moxiﬂoxacin case; other
kanamycin, one carbamazepine, one phenytoin, and one lindane case
e One case showed anti-mycoplasma IgM of 1178.3 U/mL (normal value< 770 U/mL) an
the anti-coxsackie virus B3 IgM of 130 U/mL (normal value< 30 U/mL); one case showed
antigen IgM of 102 U/mL (normal value< 36 U/mL), and anti-viral capsid antigen IgG, 1multiple drugs before the development of AGEP. Other causative
agents included terbinaﬁne, levetiracetam, kanamycin, and lindane.
(Table 2).
Neutrophilia and elevated CRP occurred in the majority of AGEP
patients in both groups. Eosinophilia was more frequently present
in patients with AGEP without drug causality, than in patients with
AGEP with drug causality (41.2% vs. 11.8%, respectively, p ¼ 0.02).
For both groups, blood cultures failed to identify any pathogens.
However, three AGEP patients without drug causality were diag-
nosed with recent EpsteineBarr virus (EBV), Coxsackie virus, and
mycoplasma infections, respectively (Table 3). There were a total of
12 cases (23.5%) of AGEP with systemic involvement, including the
liver and kidneys. However, only patients with AGEP with drug
causality experienced acute renal insufﬁciency. All patients with
systemic involvement showed complete recovery in renal and liver
function.Recruited AGEP, n ¼ 51 (%)
AGEP with drug causality,
n ¼ 34 (66.7)
AGEP without drug causality,
n ¼ 17 (33.3)
28 (82.4) 16 (94.1)
4 (11.8) 7 (41.2)
4 (11.7) 0 (0)
23 (67.6) 13 (76.5)
0 0
f ALTb 0 (0) 2 (11.8)
f ALTb 3 (8.8) 3 (17.6)







None Mycoplasma (1), Coxsackie
virus (1), EB virus (1)
1 (2.9) 0
(normal value 50e300/mL); atypical lymphocytes, normal value¼ 0; CRP, C-reactive
d as ALT> 60 U/L, and severe hepatitis was determined as ALT> 120 U/L
d as Cr> 1.8 mg/dL
cephalosporins included three cefazolin, one cefaclor, and two cephalexin cases;
s included one ibuprofen, one vancomycin, one levetiracetam, one terbinaﬁne, one
d anti-mycoplasma IgG of 2722.9 U/mL (normal value< 100 U/mL); one case showed
anti-coxsackie virus B3 IgG of 40 U/mL (normal value< 80 U/mL), anti-viral capsid
32 U/mL (normal range,< 20 U/mL).
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pathologic ﬁndings included exocytosis of polymorphonuclear
neutrophils, subcorneal or intraepidermal pustulosis, and spon-
giosis, which are characteristic for AGEP. Atypical pathologic ﬁnd-
ings accompanied with pustulosis were also observed in some
patients, including dyskeratosis or necrosis of keratinocytes, and
lymphocytoclastic vasculitis. No patients presented with Munro’s
microabscesses or psoriasiform hyperplasia (Table 3).
Discussion
AGEP is a rare condition characterized by sudden eruption of
minute, non-follicular pustules on a background of erythema, and
is usually associated with fever and neutrophilia. Drug use is the
major cause for the development of AGEP. The list of drugs reported
is extensive, but certain medications such as aminopenicillins,
pristinamycin, quinolones, terbinaﬁne, diltiazem, and anti-
malarials are associated with a higher risk for AGEP.4 In this
study, we found that beta-lactam antibiotics were the major
causative drugs for AGEP in Taiwan.
AGEP patients with drug causality were older and had a higher
rate of comorbidity, compared to AGEP patients without drug
causality, suggesting that patients in this groupmight have a higher
risk of adverse drug reactions after the use of certain medications.
One recent large-scale multinational case-control study (the
EuroSCAR study) revealed that some of the most likely drugs to
cause AGEP were pristinamycin, ampicillin/amoxicillin, quinolones,
(hydroxyl) chloroquine, anti-infective sulfonamides, terbinaﬁne,
and diltiazem.9 In this study, the percentage of patients with
identiﬁed offending drugs was lower than previous reports. One
reason may be that patients in Taiwan frequently take multiple
drugs or ingredients, and their drug histories are often difﬁcult to
establish. Another potential reason is that patients may have been
indirectly exposed to environmental antibiotics or chemical addi-
tives, further complicating the identiﬁcation of AGEP causality.
Eosinophilia is not uncommon in patients with AGEP. Roujeau
et al showed in their study that w30% of AGEP patients had
eosinophilia.3 In our study, 21.6% of all patients presented with
eosinophilia. There is still no appropriate explanation for a higher
rate of eosinophilia in AGEP patients without drug causality in this
study due to limited sample size and without a further investiga-
tion; however, potential non-drug antigens such as food additives
and environmental residual chemicals could also induce similar
AGEP immune reactions and susceptible patients continuously
exposed to these environmental antigens without caution may
have similar pustular immune reactions.
In this study, we also noted that there were three AGEP cases
induced by Chinese herbs. Two of the three patients took herb
medication for weight loss, and one of them used the Chinese herbs
as food ﬂavoring. An increase in the use of alternative and com-
plementary medicines, such as herbal medicines, has been
observed in Chinese society, and it is not surprising that herbal
medication can cause AGEP as well as other severe cutaneous
adverse reactions, since they are known to contain unsafe levels of
heavy metals (including mercury),10 synthetic drugs, or microor-
ganism contamination.11
In addition to drugs, other factors have also been implicated in
the development of AGEP, including acute infections with entero-
virus, and hypersensitivity to mercury.3 Similarly, other pathogen
infections have been known to contribute to the development of
drug hypersensitivity,12 and infectious pathogen-related AGEP hasbeen reported previously, with known causative agents including
enterovirus, cytomegalovirus, EBV, hepatitis B virus, parvovirus
B19, Escherichia coli, Chlamydia pneumonia, Echinococcus gran-
ulosus, and Mycoplasma.13 In this study, we identiﬁed three AGEP
patients without drug causality showing recent infections of EBV,
Coxsackie virus, and mycoplasma. All our patients of AGEP without
drug causality denied insect bite history. As for other infectious
pathogens, we did not survey all of them except patients with
prodrome or a recent history of suspected viral infections and EBV,
HSV, or mycoplasmawhich are of our routine works for severe drug
reactions.
Recently, Hotz et al14 reported systemic involvement of AGEP in
a retrospective study of 58 patients. Systemic involvement,
including liver, kidney, bone marrow, and lungs, was observed in
17.2% of their AGEP cases. Comparably, in this study, we found that
23.5% of AGEP cases had systemic involvement, indicating that
physicians should be educated and aware of the potential risk of
systemic involvement in AGEP.
In conclusion, we demonstrated that drugs, including Chinese
herbs, are the main causes for the induction of AGEP in a Taiwanese
population. Beta-lactam antibiotics were the major causative drug
for AGEP in this population, but some infectious pathogens may
also contribute to the development of AGEP. There is potential risk
for systemic involvement in patients with AGEP.
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